First clinical data with a novel LPA mRNA targeting siRNA, new results showing inhibition of Lp(a) oxidation by eicosapentaenoic acid, and evidence of the impact of Lp(a) testing on initiation of lipid lowering therapies were among the Lp(a) research presentations attracting attention at the American College of Cardiology congress in New Orleans, USA (28-30 March 2026). Also on the agenda was a warning that Latino patients are missing out on Lp(a) testing, reassuring news of a good correlation between serum and plasma Lp(a) levels, and latest investigations into links between elevated Lp(a) and mitral valve disorders and atrial fibrillation.
Reports by Jenny Bryan
- Encouraging Phase 1 data for SRSD216 in elevated Lp(a)
- Lp(a) oxidation linked to apo-B enrichment and reduced by EPA
- Lp(a) measurement leads to LLT initiation
- Latino patients missing out on Lp(a) testing
- Serum and plasma Lp(a) levels show good correlation
- Studies test links between Lp(a) and AF and mitral valve disorders
